A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.
This study reports the results of a trial of essential fatty acid (EFA) supplementation in psychiatric patients (predominantly schizophrenics) with movement disorders. Evidence of EFA deficiency in these patients was observed. The antidyskinetic effect of EFA supplementation was marginally significant but not clinically important. However, active treatment produced highly significant improvements in total psychopathology scores and schizophrenia subscale scores, and a significant improvement in memory.
Vaddadi
K S
KS
Department of Psychiatry, Crawley Hospital, West Sussex, England.
Courtney
P
P
Gilleard
C J
CJ
Manku
M S
MS
Horrobin
D F
DF
D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000097:blood / Q000628:therapy*; D005228:Fatty Acids, Essential / Q000008:administration & dosage* / Q000172:deficiency; D005260:Female; D006801:Humans; D008041:Linoleic Acids; D008297:Male; D008875:Middle Aged; D031665:Oenothera biennis; D010554:Personality Disorders / Q000188:drug therapy*; D010938:Plant Oils; D012559:Schizophrenia / Q000188:drug therapy*; D017965:gamma-Linolenic Acid
D014150:Antipsychotic Agents; D005228:Fatty Acids, Essential; D008041:Linoleic Acids; D010938:Plant Oils; C028498:evening primrose oil; D017965:gamma-Linolenic Acid